drugset / Trial / NCT00043394
CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.
Timeline
- Start
- 2002-09
- Primary completion
- 2003-10
- Completion
- 2003-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | agatolimod | Oligonucleotide (other) | 0.04 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.08 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.12 mg/kg | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.16 mg/kg | Subcutaneous |
| Background | Trastuzumab | Monoclonal antibody | — | — |